Active, not recruitingNCT06832371
Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia
Studying Homozygous familial hypercholesterolemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
- Enrollment
- 73 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- CHRU Lille - Centre Hospitalier Universitaire de Lille, Lille, France
- Centre Hospitalier Universitaire de Lyon (CHU Lyon), Lyon, France
- Hôpital de la Conception - Assistance Publique Hôpitaux de Marseille (AP-HM), Marseille, France
- Hôpital La Pitié Salpêtrière - Groupe Hospitalier "La Pitié Salpêtrière - Charles Foix", Paris, France
- Strasbourg University Hospital (CHU Strasbourg), Strasbourg, France
- University General Hospital of Ioannina, Ioannina, Greece
- METROPOLITAN HOSPITAL, Piraeus, Piraeus, Greece
- Policlinico di Catanzaro - A.O.U. Mater Domini, Catanzaro, Calabria, Italy
- Ospedale Sant'Anna e San Sebastiano, Caserta, Campania, Italy
- Policlinico Federico II di Napoli, Naples, Campania, Italy
- Policlinico Sant'Orsola - Università di Bologna, Bologna, Emilia-Romagna, Italy
- Arcispedale Sant'Anna - Università degli Studi di Ferrara, Ferrara, Emilia-Romagna, Italy
- Ospedale Civile di Baggiovara - A.O.U. di Modena, Modena, Emilia-Romagna, Italy
- DIMI - Dipartimento di Medicina Interna, Università di Genova, Genova, GE, Italy
- ARNAS Garibaldi, Catania, Italy, Italy
- +15 more locations on ClinicalTrials.gov
Collaborators
Amryt Pharmaceuticals DAC · Clinical Trial Consulting · CMV-Stat S.r.l.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06832371 on ClinicalTrials.govOther trials for Homozygous familial hypercholesterolemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07447648Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
- RECRUITINGPHASE2NCT07489209A Dose-exploration Study of EDP167 in HoFHEddingpharm (Zhuhai) Co., Ltd.
- RECRUITINGPHASE3NCT07037771A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)Arrowhead Pharmaceuticals
- RECRUITINGNANCT06743659Computerized Decision Support for Identification and Management of Familial HypercholesterolemiaBrigham and Women's Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT06712771A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH PatientsVisirna Therapeutics HK Limited
- RECRUITINGEARLY PHASE1NCT06458010Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)RenJi Hospital
- ACTIVE NOT RECRUITINGNCT06275724Specified Drug-use Survey of Leqvio for s.c. Injection.Novartis Pharmaceuticals
- RECRUITINGEARLY PHASE1NCT06125847NGGT006 Gene Therapy for Homozygous Familial HypercholesterolemiaFirst Affiliated Hospital Xi'an Jiaotong University
See all trials for Homozygous familial hypercholesterolemia →